Vertex Pharmaceuticals Inc
XETRA:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Vertex Pharmaceuticals Inc (VX1) under the Base Case is EUR per share.
Compared with the current market price of 227.65 EUR, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Vertex Pharmaceuticals Does
Vertex Pharmaceuticals is a biotech company that discovers and sells prescription medicines for serious diseases. Its best-known business is cystic fibrosis treatment, where it develops drugs that help correct the underlying protein defect that causes the disease. It also works on medicines for pain, sickle cell disease, beta thalassemia, and other hard-to-treat conditions.
- Headquarters
- United States of America US
- Employees
- 6 400
- IPO date
- Jul 24, 1991
Vertex Pharmaceuticals has a narrow economic moat
Patents covering Vertex’s cystic fibrosis medicines prevent rivals from selling copies, protecting its profits. Competitors must develop and win approval for their own treatments rather than simply reproduce medicines such as Trikafta and Alyftrek.
Read the full moat analysis
Revenue & Expenses Breakdown
Vertex Pharmaceuticals Inc
Earnings Waterfall
Vertex Pharmaceuticals Inc
What is the Intrinsic Value of one VX1 stock?
The intrinsic value for Vertex Pharmaceuticals Inc (VX1) under the Base Case is EUR.
Is VX1 stock undervalued or overvalued?
Compared with the current market price of 227.65 EUR, the stock appears .
